Education
About Us
Working with TipRanks
Follow Us
Bio-Techne (TECH)
NASDAQ:TECH
TECH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$46.44 - $85.57
Previous CloseN/A
Volume102.39K
Average Volume (3M)2.17M
Market Cap
$8.55B
Enterprise Value$11.79B
Total Cash (Recent Filing)$108.24M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)55.0
Beta1.07
Next Earnings
Apr 30, 2025EPS Estimate
0.51Last Dividend Ex-Date
Feb 14, 2025Dividend Yield0.59%
Share Statistics
EPS (TTM)0.98
Shares Outstanding158,087,680
10 Day Avg. Volume2,416,139
30 Day Avg. Volume2,170,129
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.01
Price to Cash Flow (P/CF)28.40
P/FCF Ratio28.40
Enterprise Value/Market Cap1.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.31
Enterprise Value/Ebitda34.46
Forecast
1Y Price Target
$82.00Price Target Upside66.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Operational MarginsThere is a path outlined for improving operating margins to approximately 38% by the fiscal year 2028.
Pharmaceutical TrendsPharma trends support TECH's recovery outlook, with large pharma recovery signs in the US and Europe.
Revenue GrowthBio-Techne is a premium growth asset with strong core business segments and growth verticals, making it well-positioned for sustainable growth.
Bears Say
Academic Spending SlowdownExpected acceleration in organic growth appears in question given the slowdown in academic spending following NIH budget cuts, potentially creating a headwind to revenue growth in the coming quarters.
Federal Funding CutsWith federal government funding cuts in NIH/academic research, increased risk is seen stemming from TECH's high exposure to this market, leading to a reduction in rating from Overweight to Sector Weight.
Macro HeadwindsMacro headwinds in academic markets could significantly impact near-term financial performance due to budget freezes.
---
Ownership Overview
0.22% Insiders
41.11% Mutual Funds
25.68% Other Institutional Investors
8.16% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
ProductionRisks related to the company’s ability to manufacture goods and services
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TECH FAQ
What was Bio-Techne’s price range in the past 12 months?
Bio-Techne lowest stock price was $46.44 and its highest was $85.57 in the past 12 months.
What is Bio-Techne’s market cap?
Bio-Techne’s market cap is $8.55B.
When is Bio-Techne’s upcoming earnings report date?
Bio-Techne’s upcoming earnings report date is Apr 30, 2025 which is in 18 days.
How were Bio-Techne’s earnings last quarter?
Bio-Techne released its earnings results on Feb 05, 2025. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.386 by $0.034.
Is Bio-Techne overvalued?
According to Wall Street analysts Bio-Techne’s price is currently Undervalued.
Does Bio-Techne pay dividends?
Bio-Techne pays a Quarterly dividend of $0.079 which represents an annual dividend yield of 0.59%. See more information on Bio-Techne dividends here
What is Bio-Techne’s EPS estimate?
Bio-Techne’s EPS estimate is 0.51.
How many shares outstanding does Bio-Techne have?
Bio-Techne has 158,087,680 shares outstanding.
What happened to Bio-Techne’s price movement after its last earnings report?
Bio-Techne reported an EPS of $0.42 in its last earnings report, beating expectations of $0.386. Following the earnings report the stock price went up 3.726%.
Which hedge fund is a major shareholder of Bio-Techne?
Currently, no hedge funds are holding shares in TECH
---
Bio-Techne Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$82.00 (66.46% Upside)
$82.00 (66.46% Upside)
Blogger Sentiment
Bullish
TECH Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 324.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.82%
12-Months-Change
Fundamentals
Return on Equity
7.82%
Trailing 12-Months
Asset Growth
-2.21%
Trailing 12-Months
Company Description
Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
---
TECH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call indicates a strong performance in the quarter, with significant growth in core areas and strategic expansion. While there are challenges, particularly in China and foreign exchange impacts, the overall outlook remains positive with expectations of continued growth and recovery in key markets.Read More>---
TECH Net revenue Breakdown
71.69% Protein Sciences
28.16% Diagnostics and Genomics
0.36% Other
---
TECH Stock 12 Month Forecast
Average Price Target
$82.00
▲(66.46% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Incyte
―
Krystal Biotech
―
Moderna
―
NewAmsterdam Pharma Company
―
Best Analysts Covering TECH
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
-7.86%
reiterated a buy rating 2 months ago
Copying Robert Wasserman's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -7.86% per trade.
---